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Abstract
Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to
manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy is often short. We
report our evaluations upon safety and efficacy of domestic subcutaneous bortezomib in elderly and frail patients candidate to
bortezomib-melphalan-prednisone (VMP) regimen. We confirmed that overall incidence of adverse events, including peripheral
neuropathy, was low, and in no case required admission to emergency service, contributing to reduce the rate of therapy
discontinuation. These results confirm the effectiveness and safety of subcutaneous bortezomib, in a real-life-experience, and
define a new possibility of safe auto-administration in a comfortable domestic setting. We suggest that domestic treatment can
significantly improve the quality of life of the patients, avoiding unnecessary transfer to the hospital without reducing treatment
efficacy.
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Introduction
The overall lifetime cancer risk is about 40% inWestern coun-
tries, and it is well known that the combined incidence for all
sites and types of cancer increases rapidly after age 60, espe-
cially in men [1].
Multiple myeloma (MM) is a hematological malignancy
frequent in elderly and frail patients, with propensity to cause
bone lesions, hypercalcemia, renal failure, and anemia [2, 3].
Bortezomib is the first-in-class proteasome inhibitor and when
associated to immunomodulatory drugs (IMiDs) and dexa-
methasone increases the overall survival (OS) inMM [2, 4–8].
Despite novel agents, MM is still an incurable disease,
especially for elderly and frail patients, who are difficult to
manage for concomitant comorbidities as the therapeutic op-
tions are limited and the response to chemotherapy is often
short lived. Unfortunately, the paucity of ultra-elderly patients
(> 80 years old) included in clinical trials has made it difficult
to define specific treatment strategies. Both in clinical trials
and in daily clinical practice, elderly multiple myeloma pa-
tients have shown lesser benefit, due to less stringent use of
proteasome inhibitors and immune-modulator reagents
(IMiDs) lenalidomide and thalidomide, and early discontinu-
ation of therapy for limited access to hospitals. Recent re-
search in this patient population, however, has begun to reveal
some important principles, such as the need for a comprehen-
sive assessment as the basis for planning treatment to over-
come the assumption that all or even most elderly patients are
too frail to tolerate standard chemotherapy [9].
Data on the feasibility and efficacy of current standards of
care are therefore lacking in frail patients. Age itself is far less
important as a predictor of clinical outcome than is the older
patient’s physical, mental, emotional, and functional status. It
now appears that, when given the same standard therapy,
otherwise-healthy older patients can gain benefits comparable
to those gained by younger patients. The high discontinuation
rate and impaired quality of life could contribute to loss of
efficacy in frail patients.
The current approach for elderly patients includes long-
term treatment with at least nine cycles of induction chemo-
therapy, in order to achieve a sequential disease control
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approach [5, 9, 10]. Bortezomib has been shown safe, not
requiring dosage adjustments in patients with renal impair-
ment, skin or lung fibrosis, or mild hepatic impairment [11].
Recommended dose and schedule of bortezomib is 1–
1.3 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle, for up
to eight cycles, administered by 3–5/s intra venous (IV) bolus.
However, the once-weekly schedule significantly reduced the
incidence of adverse events, including peripheral neuropathy
(PN) and decreased the rate of discontinuation compared with
the twice-weekly schedule, resulting in similar cumulative
bortezomib doses, an important predictor of outcome [12–14].
Since IV administration may present some difficulties for
patients with poor venous access and could limit dosage flex-
ibility, the phase-3 MMY-3021 trial evaluated the efficacy of
subcutaneous (SC) bortezomib administration leading to its
approval by FDA in January 2012, by Health Canada in
March 2012 and by CHMP-EMEA in June 2012. In general,
safety data were similar for the SC and IV treatment groups,
with a more tolerable profile for SC injection, due to a reduced
incidence of neuralgia, peripheral neuropathy and thrombocy-
topenia, without affecting efficacy [15–18].
Millennium Pharmaceuticals recommended precaution in
the vial reconstitution and administration, since the
reconstituted concentration for subcutaneous administration
(2.5 mg/mL) is greater than the reconstituted concentration
for IV administration (1 mg/mL), even if preliminary data
about PK and PD arising from MMY-3021 and CAN-1004
trials, showed that SC injection concentration (2.5 vs 1 mg/
mL) had no appreciable effect [16]. Compared with IVadmin-
istration, SC administration resulted in equivalent bortezomib
plasma exposure, without affecting PK and PD parameters.
When bortezomib (3.5 mg in manufacturer’s vial) is
reconstituted with 1.4 mL NS, is physically and chemically
stable for at least 1 week at 4 °C when stored in either the
manufacturer’s original glass vial or in a syringe and not ex-
posed to light [19, 20].
Subcutaneous bortezomib administration has huge advan-
tages to treat patients with poor venous accesses, and gener-
ally, it is convenient for both patients and physicians because
it overcomes problems related to a prolonged intravenous in-
fusion or the insertion of a long-term central venous access
device. Moreover, overall incidence of peripheral neuropathy
is lower with the subcutaneous administration in comparison
with the intravenous route, reducing the possibility of a ther-
apy discontinuation related to this adverse event [17].
In recent years, for some non histotoxic anti-cancer drugs,
such as rituximab, trastuzumab, or cladribine, the subcutane-
ous route, as alternative to the intravenous one, has been suc-
cessfully compared and the possibility of a self-administration
modality for adequately informed patients or adult care-givers
was also demonstrated [21, 22].
Based on this assumption, we designed an outpatients’ pro-
gram for domestic injection of SC bortezomib, associated to
melphalan and prednisone (VMP) frail patients with difficul-
ties to attain the hospital: evaluations upon the efficacy and
safety are herein presented.
Material and methods
Patients selection
From January 2009 to June 2017, 63 frail patients requiring
bortezomib for the treatment ofMM, in association with orally
administered prednisone and melphalan (VMP), performed
SC injection of bortezomib at home for personal or logistic
reasons. Initially, the drug was administered by qualified per-
sonnel; subsequently, the patient or an adult care-giver learned
to inject it subcutaneously in the deltoid muscle area.
Bortezomib was supplied in ready-to-use plastic syringes,
where the drug was appropriately constituted in saline solu-
tion, under hood in sterile conditions by qualified personnel,
few hours before delivering it to patients. Therefore, with an
optimal storage stability temperature of 4 °C, the syringes
were easily transported to patient in a refrigerated container,
without affecting the chemical stability of the compound [19,
20].
Median age was 78 years old (range 59–87), with median
Karnofsky PS 60% (range 40–90%).
Because of high dose steroids and bortezomib, the only
exclusion criteria were psychiatric diseases or grade 2 or
higher peripheral neuropathy. All patients were adequately
informed in accordance with the Declaration of Helsinki.
Treatment
Patients received 4-week cycles of melphalan (9 mg/m2) and
prednisone (60 mg/m2) on days 1 to 4, bortezomib (1.0–
1.3 mg/m2) on days 1, 8, 15, and 22 (mean number of cycles
9, r. 3–12), according to a schedule adapted for frail patients
[23–25].
The first cycle was usually administered at hospital to as-
sess and confirm the safety of this route. Only 4 patients
(6.3%) received also their first course at home, due to very
poor clinical status.
Each cycle was proposed every 28 days for a total of 9
planned courses.
All patients received treatment with bisphosphonates every
4 weeks during the study. An antibiotic and antiviral prophy-
laxis was carried out with cotrimoxazole (800 mg twice a day,
twice a week) and acyclovir 400 mg/die twice a day.
Supportive therapy with erythropoietin (EPO) and granulo-
cyte colony-stimulating factor (G-CSF) was administered ac-
cordingly to ASH/ASCO guidelines [26], as reported in our
previous experience in the same setting [27, 28].
3112 Support Care Cancer (2018) 26:3111–3116
Safety and efficacy assessment
Each patient’s medical history was recorded on day 1 of each
cycle. Physical examinations were conducted and blood was
collected for hematology, renal and liver function tests 2 days
before. Then, laboratory parameters were evaluated monthly
or every 2 months, depending by clinical status of patient and
disease stage.
Adverse events were graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI-CTC) criteria, version 4.0 [24].
Efficacy assessment was recorded after cycle 2 and every
other cycle thereafter: myeloma protein evaluation by measur-
ing serum and urine M component, beta-2 microglobulin, al-
bumin and C-reactive protein (C-RP) and assessment of dis-
ease response according to the criteria of the International
MyelomaWorking Group [29]. Disease response was defined
as complete remission (CR), very good partial remission
(VGPR), partial remission (PR), stable disease (SD), progres-
sion disease (PD), or not valuable (NV).
Statistical analysis
Descriptive statistics were generated for analysis of results and
p value < 0.05 was considered significant. Qualitative results
were summarized in counts and percentages. Overall response
rate (ORR) was defined as PR or better (CR+VGPR+PR).
Progression free survival (PFS) was calculated from the time
of inclusion until the date of progression, relapse, death or the
date the patient was last known to be in remission and ana-
lyzed with Kaplan-Meier tests. Standard errors were calculat-
ed by the method of Greenwood, the 95% confidence intervals
are computed as 1.96 times the standard error in each
direction.
All calculations were performed using Graph Pad Prism
version 5.00 for Windows, Graph Pad Software, San Diego
California USA, www.graphpad.com.
Results
The median number of administered cycles was 7 (range 1–9),
with a mean duration of treatment of 7.3 ± 0.7 months.
Delivery of planned doses was as follows: 45/63 (71%) of
patients received all doses of VMP, (18/63) 29% missed from
5 or more doses. Overall, 59 patients (93.6%) received all the
doses of the cycles in a domestic setting, excepting 4 patients
(6.3%), who received only the first administration at hospital,
due to their frail clinical conditions, as mentioned above.
Treatment was interrupted after first two cycles in 18 pa-
tients for patient’s will (n = 3), progressive disease (n = 9), and
infection (n = 6). Drug reduction or delay administration was
required only in 3 cases; thus, 45/63 of patients received all
planned cycles at full dosage (Table 1).
The most common adverse events occurred during chemo-
therapy administration are reported in Table 2.
In about half of patients, the treatment was complicated by
hematological toxicity, grade 3–4 in 37%. Thrombocytopenia
was the most common hematologic toxicity, with grades 3–4
in 37%, without requiring platelet transfusion. Anemia grade
3–4 affected 19% of patients, and red blood cells were trans-
fused in 13% of cycles, despite of EPO support. Neutropenia
grade 4 affected 5% of patients, while G-CSF administration
was needed to support 27 cycles (29%).
Among extra-hematological toxicities, nausea, vomiting,
and diarrhea were mild, affecting 10% of cycles.
Constipation was most commonly reported, especially at first
2 courses. Peripheral neurotoxicity was referred by two pa-
tients only.
Despite antibiotic and anti-viral prophylaxis was given ac-
cording to internal guidelines [24, 26–28], Herpes Zoster re-
activation occurred in three patients, managed successfully
with standard antiviral treatment.
Three patients (3/63, 4.7%) were hospitalized for pneumo-
nia (median days of hospitalization 6, with a range of 4–16)
and received intravenous antibiotic treatment with resolution
of infectious episodes. No patient died during treatment, and
all of them re-started VMP with no further consequences.
VMP did not affect the renal function.
Out of 45 patients who completed at least two cycles, the
overall response rate (CR+VGPR+PR) was 72% (32 patients),
including 32% (14 patients) negative-immunofixation com-
plete remissions, 22% (10 patients) very good partial remis-
sions and 18% (8 patients) partial remissions; 18% (8 patients)
obtained a stable control of disease and only one patients
progressed after five cycles.
After median follow up of 34.5 months (range 2.7–
50 months), the median PFS was 12.3 months (Fig. 1), similar
to what previously reported in similar settings of patients treat-
ed up-front with SC bortezomib in VMP regimen [17, 30].
Discussion
The combined strategy of care as domestic and outpatient
setting for hematological diseases is still in debate. Given
the costs of novel agents, the long-term treatment for frail
patients with logistic limitation at home has been proposed
as a suitable option for improving patient quality of life in a
cost-saving approach for bortezomib-based regimens in MM.
Data about efficacy and safety were similar to those observed
in major clinical trials [2, 30–32] and other previous experi-
ence [5, 24, 25, 33–35]. In a recent report, Touati M. and
colleagues showed the achievement of 16.5% of cost saving
with the administration of two thirds of injection at home,
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representing approximately 189 € saved per bortezomib injec-
tion in a retrospective study covering a geographical area
comprising three Hematology units [36].
We reported our single-center experience in a similar set-
ting of patients, confirming the effectiveness and safety of SC
bortezomib, with the equal incidence of adverse events for
outpatients’ or domestic administration.
Based on final analysis of phase III MMY-3021 study
which investigated the non-inferior efficacy with subcutane-
ous versus intravenous bortezomib associated to dexametha-
sone, best response rate was 52% in each arm, including 23
and 22% complete or near-complete responses with subcuta-
neous and intravenous bortezomib, respectively. Time to pro-
gression, progression-free survival and overall survival were
comparable with subcutaneous versus intravenous
bortezomib, with lower rate of peripheral neuropathy in SC
bortezomib arm.
In real-life clinical practice, there is a common feeling to
use only oral therapies for elderly and frail patients. Based on
phase III VISTA trial, duration and quality of response upon
VMP treatment improved global health status, pain, and ap-
petite loss scores in elderly patients, in particular using the
weekly schedule 1–8–15-22 [2], confirming the superiority
of VMP on MP. Even if in absence of a formal prospective
trial, a retrospective study showed that VMP was an indepen-
dent predictor of longer PFS and OS. Indeed, in a control-case
matched analysis, PFS and OS were prolonged in patients
who received VMP in comparison with those treated with
melphalan-prednisone-thalidomide (MPT) [37].
Based on our observations, obtained in a real-life experi-
ence, domestic treatment could significantly improve the qual-
ity of life of elderly patients, avoiding unnecessary transfer to
Table 1 Baseline characteristics of patients
Characteristics Patients
Total patients 63
Sex
Males, n (%) 29 (46)
Age, years
Median, (range) 68 (59–87)
Paraproteins (isotype), n (%)
Immunoglobulin G 39 (62%)
Immunoglobulin A 16 (25%)
Light chain only 8 (13%)
Stage ISS
I 12 (19%)
II 22 (35%)
III 29 (46%)
Median Karnofsky PS (range) 60% (40–90)
Baseline hemoglobin, g/dL (range) 11.6 (8.7–14)
Baseline platelet count, · 10^9 161 (83–357)
Bone marrow infiltration > 50%, n (%) 41 (65%)
C-reactive protein, mg/l (range) 2.6 (1.7–26.2)
Lactate dehydrogenase, U/l (range) 173 (131–459)
Beta-2 microglobulin, mg/L 4.3 (0.9–16.4)
Serum albumin, g/dL (range) 3.4 (2.9–4.6)
Cytogenetics
del13q 9 (14%)
t(4; 14) 5 (8%)
del 17p 8 (12%)
normal 29 (46%)
N.V. 12 (19%)
Table 2 Adverse events in the cohort of elderly and frail patients
included in the study
No. events (%) Total Grade 3 Grade 4
Hematologic
Trombocytopenia 31(50) 13(21) 10(16)
Anemia 28(45) 11(18) 1(1)
Neutropenia 32(51) 22(35) 3(5)
Gastrointestinal
Nausea 29(46) 2(3) 1(1)
Diarrhea 30(48) 4(6) 0
Vomiting 19(30) 2(3) 0
PSN 32(51) 6(1) 1(1)
Infections
Pneumonia 9(15) 4(6) 1(1)
Herpes Zoster n [11] 2(3) 0
Total and grade 3/4 adverse events were reported in patients underwent to
domestic treatment. PSN = peripheral sensory neuropathy
PSN peripheral sensory neuropathy
Fig. 1 Progression free survival in MM patients treated up-front with
VMP regimen, using subcutaneous bortezomib, in a domestic setting
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the hospital without reducing treatment efficacy. Multi-center
studies are needed to address the schedule and feasibility in
larger series to improve this approach in clinical practice.
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